Seven Pharmacist was founded in 2014 on a simple premise: a therapeutic should be as well-governed as it is well-designed. Two researchers and a corporate governance lawyer built the company around one rule — no program advances a phase without independent sign-off on the data.
That rule shaped everything that followed, including a board structure that puts outside directors in the majority from day one, long before public listing required it.
Read More
We measure a program's success first by what the data shows, second by what regulators decide, and only then by what it returns. That ordering is written into board policy, not just a slogan — committee charters require it explicitly.
Seven of our nine board directors hold no executive role at the company, re-assessed annually for independence.
See Our Facilities
A condensed timeline from founding to today's footprint.
Founded in Wilmington with a three-person board and a single oncology candidate.
Expanded to nine directors, seven independent, ahead of Series C funding.
Dermalix received its first regulatory approval and reached patients.
Eleven active programs across two manufacturing sites and three therapeutic teams.
What struck me about Seven Pharmacist wasn't just the science — it was how seriously the board took its oversight role. Every milestone we hit as a partner was checked against real data, not just a press release. That discipline is rare.Dr. Lena Marsh, Former FDA Reviewer